







Muscle Relaxants

Lecture no.3

Color Index:

- Main Text
- Important
- Females' Slides
- Males' Slides
- Drs' Notes
- Extra info.




Objectives

- Identify classification of skeletal muscle relaxants.
- Describe the pharmacokinetics and dynamics of neuromuscular relaxants.
- Recognize the clinical applications for neuromuscular blockers.
- Know the different types of spasmolytics.
- Describe the pharmacokinetics and dynamics of spasmolytic drugs.
- Recognize the clinical applications for spasmolytic drugs.

Skeletal muscle relaxants (SKM relaxants):



- Are drugs used to induce skeletal muscle relaxation.
- Drugs that can act peripherally at the neuromuscular junction/fiber itself or centrally in the cerebrospinal axis to reduce muscle tone and/or cause paralysis. (classified according to site of action).





Indications of muscle relaxants

Males' Slides:

- → These agents are used primarily in conjunction with general anesthetics to provide muscle relaxation for surgery.
- → While centrally acting muscle relaxants are used mainly for painful muscle spasms and spastics neurological conditions.

Neuromuscular Junction





Mechanism of action of neuromuscular blockers (extra explanation). Normally in the neuromuscular junction, the acetylcholine will attach with the acetylcholine receptors (in skeletal muscle the receptors) are nicotinic receptors type 1 after that a lot of changes will happen so that the muscle contracts. However, the Neuromuscular blockers will block the nicotinic receptors so acetylcholine cannot bind with the receptors, thus, preventing its action (muscle contraction) and if the muscle won't contract it'll relax.

Thanks to Team441

Skeletal Muscle Reactants - MOA

Males' Slides:

- Normal:Ach+Nm receptor \to Na channel opening \to Na ion transportation \to depolarization \to muscle contraction
- Site of action of both competitive and depolarizing blockers is the end plate of skeletal muscle fibres specifically Nm receptors.

Peripheral acting SKM relaxants (Neuromuscular blockers):

Act by blocking NM junction or motor end plate leading to skeletal muscle relaxation. NMB drugs interfere with transmission at the NM end plate & lack CNS activity.

These are competitive antagonists meaning they compete with the other drugs on the receptor binding site to inhibit its action unlike noncompetitive antagonists which go and bind to the allosteric site.

Competitive

("non depolarizing blockers")

E.g.

- Atracurium
- Mivacurium
- Pancuronium
- d-tubocurarine (prototype)
- Vecuronium
- Rocuronium

Depolarizing blockers

E.g.

Succinylcholine

(it is an agonist and all agonists bind to receptors)


Competitive Blockers (non-depolarizing) Peripherally Acting:

Mechanism of action:

 \diamond Are competitive antagonists for Ach at the nicotinic receptors present in <u>post</u> junctional membrane of neuromuscular junction or motor end plate. But have no intrinsic activity \rightarrow Block Nm receptor binding from Ach \rightarrow prevent depolarization \rightarrow prevent contraction \rightarrow muscle relaxation.

- ❖ No depolarization of post junctional membrane (non depolarizing).
- * Action can be reversed or overcome by increasing cholinesterase inhibitors (neostigmine) which increase Ach concentration at motor end plate.

-Acetylcholinesterase (AchE) breaks down or hydrolyzes Ach, so AchE inhibitors will increase Ach concentration."443 note"



Drugs

Long acting:

- -D-tubocurarine (prototype). First muscle relaxant used clinically
- -Pancuronium

Intermediate acting:

- -Atracurium
- -Vecuronium
- -Rocuronium

Short acting:

-Mivacurium

443 note:

'If the drug ended with curium or curonium it means that it is a SKM relaxant acting peripherally and mainly competitive'

Pharmacokinetics

- They are polar compounds.
- Inactive orally & taken parenterally.
- > Do not cross BBB (no central action).
- > Do not cross placenta. (can be used for pregnant women)
- Metabolism depend upon kidney or liver.

EXCEPT:

- Mivacurium (degraded by acetylcholinesterase).
- Atracurium (spontaneous degradation in blood).

Pharmacological action

- *Skeletal muscle relaxation (Small rapidly contracting muscles of face, eyes ,fingers ,neck ,trunk muscle ,intercostal muscles,diaphragm).
- Recovery comes from REVERSE MANNER starting with diaphragm, last is face and eyes.
- ♦ They produce different effects on CVS (cardiovascular system).
- ❖ Some release histamine and produce hypotension.
 - ➤d-Tubocurarine (severe release of histamine) "the most one"
 - **>**Atracurium
 - > Mivacurium
- Others produce tachycardia (Increase Heart rate)
 - **≻**Pancuronium

1- D-Tubocurarine (curare)

| i Diabodululiio (dululo) | | | |
|------------------------------------|---|--|--|
| Duration | 1-2 Hours (long duration) (443 note: if the excretion is mainly in the Kidney (high percentage), this means long duration of action. All of them have relatively short half life) | | |
| Metabolism and excretion | Eliminated by kidney 60% - liver 40% | | |
| Side effects | Histamine releaser leading to: 1.Bronchospasm (constriction of bronchial smooth muscles) 2.Hypotension (Blocks autonomic ganglia) 3.Tachycardia | | |
| Uses | Not used clinically due to adverse effects. (side effects) | | |
| Notes | More safer derivatives are now available to be used in clinical settings. | | |
| 2-Atracurium | | | |
| Duration | 30 min (intermediate duration) | | |
| Metabolism and excretion | Eliminated by non enzymatic chemical degradation in plasma (spontaneous hydrolysis at body pH) no enzymes involved يفكك نفسه | | |
| Side effects | Transient <u>hypo</u> tension (due to histamine release), bronchospasm. | | |
| Uses 🜟 | Used in liver failure and kidney failure (drug of choice) | | |
| Contraindication (not good for) | Asthmatic patients because it releases histamine leading to bronchospasm | | |

Potency As potent as curare (1.5)

Notes

Anti-histamine pretreatment may prevent these side effects.
No effect on muscarinic receptor nor ganglia

3-Mivacurium

Duration

15 min (The shortest duration) of all competitive neuromuscular blockers.

Metabolism and excretion

Fast onset of actionMetabolized by pseudo-cholinesterase.

Dr's note: Enzyme present in plasma excretion that breaks down any ester (442).

Side effects

Transient <u>hypo</u>tension (due to histamine release).

Uses

Used with liver or kidney failure patients. (Mivacurium & Atracurium don't depend on the kidney or liver for metabolism. Remember?)

Contraindication (not good for)

Longer duration in patient with liver disease (enzymes come from the liver, so liver diseases will prevent forming the enzyme that metabolize this drug) or genetic cholinesterase deficiency or malnutrition (lead to protein deficiency which is important to form enzymes)

Notes

•Chemically related to atracurium Mivacurium induced prolonged muscle paralysis.

Can be reversed by acetylcholinesterase inhibitors such as edrophonium acetylcholinesterase inhibitors increase the Ach level in NMJ and displace Mivacurium from nicotinic receptors in NMJ.

"team 43"

4-Pancuronium

Duration

Long duration of action(1-2 hours) (metabolic products have some NM blocking activities)

Metabolism and excretion

Metabolized in liver and excreted by the kidney (80%) (renal)

- Side Effects
- Increase norepinephrine release from adrenergic nerve endings.
 Antimuscarinic action (block parasympathetic action, atropine-like action)
- ❖ Blocks muscarinic receptor in SA sinoatrial node.
- ·

Contraindication (not good for)

Patient with coronary diseases or kidney diseases since 80% of excretion occurs there

<u>Hyper</u>tension, tachycardia.

of kidney diseases since 60% of excretion occurs there

Potency

More potent than curare (6 times)

5-Vecuronium

Intermediate duration (40 min)

Duration

| Metabolism and excretion | Metabolized mainly by liver & Excreted mainly in bile. | | |
|------------------------------------|---|--|--|
| Advantages | No histamine release. No tachycardia. No atropine like actions. (No antimuscarinic action) No ganglion block. | | |
| Uses | Good for patients with <u>renal failure</u> because its excreted by the bile good for cardiac patients because it has no antimuscarinic effect (no release of norepinephrine therefore no tachycardia) Team439 | | |
| Contraindication (not good for) | <u>Liver failure</u> patients since its metabolised by the liver and excreted in the bile "443 note" | | |
| Notes | More potent than tubocurarine (6 times). | | |
| 6-Rocuronium *FEMALE SLIDES ONLY* | | | |
| Duration | Intermediate duration | | |
| Metabolism and excretion | Biliary excretion. | | |
| Advantages | No histamine release. No tachycardia. No vagal blockade =atropine like actions | | |

Depolarizing Peripherally Acting NMBs

Mechanism of action:

❖ Combine with nicotinic receptor in post-junctional membrane of neuromuscular junction→ initial depolarization of motor end plate → muscle twitching→ Persistent depolarization(the depolarized membranes remain depolarized & unresponsive to subsequent impulses (i.e, a state of depolarizing blockade) → Skeletal muscle relaxation
 ❖ Not reversed by cholinesterase inhibitors




FIGURE 27-5 Schematic dagram of the interactions of drugs with the actylcholine receptor on the end plate channel (structures are sarely symbole). Tags: The action of the normal agenta, accylcholine (red) in opening the channel. Battom, left: A mondepolarizing acceptance of the normal agenta, accylcholine (red) in opening the channel. Battom, left: A mondepolarizing the polarized placker, e.g., acceptable(note (blue), both occuping the receptor and looking the channel. Normal channer of the channel gas a prevented and the blocker may move rapidly in and out of the pore. Depolarizing blockers may desensize the end plate by occupying the receptor and causing persistent depolarization. An additional effect of drugs on the end plate them also considerable and the complete of the complete and the co

Drugs

Succinylcholine (suxamethonium)

Pharmacokinetics (only in females' slides)

❖ Fast onset of action (1 min)

❖ Short duration of action (5-10 min.).

Metabolized by pseudocholinesterase in plasma.

❖ Half life is prolonged in:

➤ Neonates (Low enzymes)

➤ Elderly (Liver function declined due to aging)

➤ Pseudocholinesterase deficiency (liver disease or malnutrition or genetic cholinesterase deficiency).

Pharmacological action

• Skeletal muscles: initial twitching → relaxation

• Hyperkalemia (due to muscle contraction): Cardiac arrest.

• CVS: arrhythmia

• Eye: increase intraocular pressure (due to contraction of extraocular muscle).

• Apnea: Prolonged apnea & paralysis can occur in case of pseudocholinesterase or plasma cholinesterase deficiency

Contraindication (not good for)

• Glaucoma (high eye pressure)

• Patient with cardiac diseases



• Hyperkalemia (elevated levels of potassium in the blood serum)

• CVS arrhythmia

• increased Intraocular pressure contraindicated in glaucoma

• Can produce malignant hyperthermia (severe muscle contraction)

• May cause succinylcholine apnea* due to deficiency of pseudo-cholinesterase.

*Prolonged apnea and paralysis can occur with succinylcholine and mivacurium in case of plasma cholinesterase deficiency.

Summary of Neuromuscular Blockers

| Drug | Duration | Side effects | Notes |
|--------------|---------------|--|--|
| Tubocurarine | Long (1-2h) | -Hypotension | -Renal failure |
| Pancuronium | Long (1-2h) | -Tachycardia | -Nellat laitule |
| Atracurium | Short (30min) | -Transient Hypotension -Histamine release | -Spontaneous degradation -Used in liver and kidney failure |
| Vecuronium | Short (40min) | -Few side effects | -Liver failure |
| Mivacurium | Short (15min) | -Similar to Atracurium | -Metabolized by pseudocholinesterase -Cholinesterase deficiency |
| | | | |

-Hyperkalemia

-Arrhythmia

-Increase IOP

Succinylcholine


Short (10min)

-CVS diseases

-Glaucoma

-Liver disease

Uses of Neuromuscular Blockers



Drugs and diseases that modify the effects of NMBs

FEMALE SLIDES ONLY

Diseases:

Myasthenia gravis is a disease which already cause muscle relaxation, in turn it causes an increase in response to muscle relaxants.

Drugs:

Drugs as aminoglycosides (e.g.streptomycin), magnesium sulphate and general anesthetics can potentiate or enhance the effect of neuromuscular blockers.

Spasmolytic Drugs

(They reduce muscle spasm in spastic states)

| Muscle Relaxant | Baclofen | Diazepam (Benzodiazepines) | Dantrolene |
|-----------------|---|----------------------------------|---|
| Action | Centrally acting | | Directly Acting |
| Acts on | GABA agonist - acts on spinal cord | Facilitate GABA action on CNS | Direct action on skeletal muscles. Mechanism of action: Acts directly on skeletal muscles. It inhibit excitation-contraction coupling in the muscle fiber by binding to ryanodine receptor 1. Ryanodine receptor mediate the release of calcium from sarcoplasmic reticulum, an essential step in muscle contraction. |
| Clinical uses | They reduce muscle spasm and stiffness caused by neurological disorders as: • Spinal cord injury • Cerebral stroke • Cerebral palsy • Multiple sclerosis | | All on the left + • Orally, IV, (t 1/2 = 8 - 9 h) • Used in the treatment of: 1. Spastic states 2. Malignant hyperthermia |

Malignant Hyperthermia

only in females' slides

It's a rare inherited condition that occurs due to inability to bind calcium by sarcoplasmic reticulum in some patients to genetic defect, and also it is an example of idiosyncrasy*.

Sensitive to some drugs such as:

- General anesthesia e.g. halothane
- NMBs e.g. succinylcholine

*Abnormal unexpected side effects such as anaphylaxis from penicillin

Causes \uparrow Ca release, muscular rigidity, metabolic acidosis, tachycardia and hyperpyrexia (high body temperature >41.5C)

MCQs

| Q1.Which of the following drugs should not be considered if a patient has asthma? | | | | |
|---|---------------|------------------|-------------------|--|
| a) Vecuronium | b) Atracurium | c) Suxamethonium | d) Pancuronium | |
| Q2.What is the best choice of drug to give to a patient with liver or kidney failure ? | | | | |
| a) Diazepam | b) Atracurium | c) Tubocurarine | d) D-Tubocurarine | |
| Q3.Which of the following drugs should not be considered for a patient with CVS problems? | | | | |
| a) Atracurium | b)Vecuronium | c) Pancuronium | d) Rocuronium | |
| Q4.Where does the metabolism of Atracurium occur? | | | | |
| a) Blood | b) Liver | c) Kidney | d) Bile | |
| Q5.Which of the following acts on the CNS? | | | | |
| a)Atracurium | b)Dantrolene | c)Diazepam | d)Suxamethonium | |

Answers: 1)B 2)B 3)C 4)A 4)A

MCQs

| Q6. Which of the following NM blockers gets hydrolyzed at body pH? | | | | |
|--|---------------|--------------------------------|-------------------|--|
| a) Pancuronium | b) Atracurium | c) Vecuronium d) Suxamethonium | | |
| Q7. Which of the following has no histamine release? | | | | |
| a) Vecuronium | b) Atracurium | c) Mivacurium | d) Curare | |
| Q8. Which of the following drugs block the parasympathetic action & muscarinic receptor? | | | | |
| a) Pancuronium | b)Atracurium | c) Vecuronium | d) D-Tubocurarine | |
| Q9. Which of the following drugs is metabolized by pseudocholinesterase? | | | | |
| a) Vecuronium | b) Atracurium | c) Mivacurium | d) Pancuronium | |
| Q10. Which drug is most likely to cause hyperkalemia? | | | | |
| a)Baclofen | b)Dantrolene | c)Pancuronium | d)Succinylcholine | |

Answers: 6)B 7)A 8)A 9)C 10)D



Define skeletal muscle relaxants?

drugs used to induce skeletal muscle relaxation

2

What is the mechanism of action of peripheral acting drugs?

relaxation

They act by blocking neuromuscular junction or motor end plate leading to skeletal muscle

3

Why avoid use of pancuronium for patients with coronary diseases?

- Antimuscarinic action (block parasympathetic action, atropine-like action).
 - Increase norepinephrine release from adrenergic nerve endings.
 - Hypertension, tachycardia.

4

If a patient comes with an overdose of a competitive muscle relaxant, how can you treat the patient?

by neostigmine

Team Leaders:



Rakan Almutib

Shoug Albattah

Team Members:

Khalid Alkanhal

Jenan Alsayari

Omar Alattas

Lama Alahmari

Waleed Alanazi

Wsaif Alotaibi

Ali Al-Abdulazem

Nora Alturki

Saleh Alotaibi

Sahar Alfallaj

• Fawaz Almadi

Madaen Alarifi



Contact us at: pharmacology.444ksu@gmail.com